Skip to main content

Table 1 Clinical characteristics of screened patients

From: Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality

Characteristic* Overall Group
(n = 53)*
Non-Metformin User
(n = 26)
Metformin User
(n = 27)
P-value‡
   No. (%) or Mean ± SD  
Age – yrs 76.5 ± 8.6 78.2 ± 8.5 74.9 ± 8.7 0.17
Sex – male 30 (57) 16 (62) 14 (52) 0.48
Weight (kg) 82 ± 25 80 ± 22 84 ± 28 0.74
Serum Creatinine (μmol/L) 135 ± 64 147 ± 75 123 ± 49 0.17
Creatinine Clearance (ml/min) 49 ± 23 45 ± 18 53 ± 26 0.19
A1c (%) 7.3 ± 0.02 6.8 ± 1.2 7.7 ± 2.6 0.22
Heart Failure Medications     
   Beta-Blockers 38 (72) 18 (69) 20 (74) 0.70
   ACE Inhibitors or ARBs 51 (96) 26 (100) 25 (93) 0.49
   Calcium Channel Blockers 18 (34) 8 (31) 10 (37) 0.63
   Antiplatelet Agents 44 (83) 21 (81) 23 (85) 0.73
   Digoxin 9 (17) 4 (15) 5 (19) 1.0
   Spironolactone 12 (23) 5 (19) 7 (26) 0.56
   Lipid Therapy 41 (77) 19 (73) 22 (82) 0.47
   Nitrates 10 (19) 4 (15) 6 (22) 0.73
Diabetes Medications     
   Insulin 23 (43) 15 (58) 8 (30) 0.039
   Sulfonylureas 8 (15) 3 (12) 5 (19) 0.70
   Thiazolidinediones 4 (8) 1 (4) 3 (11) 0.61
   Meglitinides 2 (4) 1 (4) 1 (4) 1.00
  1. * – five patients refused to have data included
  2. † – 34 people had A1c assessed in previous 3 months; 15 people in non-metformin user and 19 people in metformin user groups
  3. – for comparison between non-metformin and metformin group